News - CQDM recently launched a new funding program for joint projects between Quebec and Ontario. The Québec/Ontario competition aims to fund the development of new enabling technologies and processes that have the potential to facilitate or accelerate the discovery or the development of new drugs. The program is opened to all researchers from academic institutions or private organisations based in Ontario or Quebec.
News - CIHR has ranked MicselonTM as the best translational life science project in Canada (no 1 among more than twenty projects). Preclinical data strongly suggest that MicselonTM is ideally suited to become a first-in-class therapy against urinary retention problems and related health problems (urinary tract infections, sepsis, etc.) in patients chronically suffering of spinal cord injury.
News - Official launch of the Genome Canada Competition in Bioinformatics and Computational Biology 2012. The Request for applications and the registration form are available on the Génome Québec Website (www.genomequebec.com). Please email the registration form to Génome Québec at email@example.com by F riday, July 20, 2012, 5:00 p.m. Registration is mandatory to submit a proposal in this competition.
News - CQDM is pleased to announce the launch of a new funding program for joint projects between Quebec and Ontario. The main goal of this funding program is to strengthen biomedical research in Quebec and in Ontario by the alignment of scientific and business resources and expertise. Ontario and Quebec are well recognized for the excellence of their research and their capacity to innovate. The collaboration will allow the two provinces to capitalize on their respective strengths and to foster innovation and competitiveness in the life sciences sector.
News - Aeterna Zentaris announced that data from two Phase 2 trials in renal cell carcinoma for the Company's oral anticancer drug, perifosine, have been published in the June 2012 issue of Cancer, a publication of the American Cancer Society.
News - To subdue a fast-moving pandemic, governments need fast moving scientists and labs and manufacturing facilities able to churn out vaccines targeted to the deadly viruses. Speedy delivery of vaccines is exactly the business of Medicago, a Quebec-based biotech with manufacturing facilities in Quebec and North Carolina.
News - DiagnoCure, a Quebec life sciences company that develops and commercializes high‐value cancer diagnostic tests, today announced that the Company will present a review of its business strategy at the Bloom Burton & Co. Healthcare Investor Conference on Thursday, June 21, 2012, at 9:30 AM (EDT). The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and European investors who are interested in the latest developments in the Canadian healthcare sector.
News - BiopolisQuébec, the alliance of the leading Quebec organizations (Montréal InVivo, Québec International et Sherbrooke Innopole) dedicated to promoting the life sciences sector internationally and Life Sciences Ontario, the voice of life sciences in Ontario, have held today in Montreal a strategic workshop. This workshop followed a first event held on December 6th, 2011 in Toronto within the framework of the memorandum of understanding signed by the two organizations.
News - Aeterna Zentaris announced that Phase 1 trial results for the Company's oral anticancer compound, perifosine, in multiple myeloma, have been published in the online May 2012 issue of the British Journal of Haematology. The article outlines the safety profile and encouraging clinical activity of perifosine when combined with lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma.
News - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Johanna Bendell, MD, Director of Gastrointestinal Cancer Research and Associate Director of Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, presented Phase 3 results for perifosine in refractory colorectal cancer yesterday, at the American Society of Clinical Oncology (ASCO) Annual Meeting which is being held in Chicago. Dr. Bendell was the lead investigator of the trial. Data showed no benefit in overall survival when adding perifosine to capecitabine in the refractory colorectal cancer setting, confirming top line results previously disclosed by the Company on April 2, 2012.